CN109010343A - 吡唑并嘧啶衍生物治疗PI3Kδ相关病症的用途 - Google Patents
吡唑并嘧啶衍生物治疗PI3Kδ相关病症的用途 Download PDFInfo
- Publication number
- CN109010343A CN109010343A CN201810796220.8A CN201810796220A CN109010343A CN 109010343 A CN109010343 A CN 109010343A CN 201810796220 A CN201810796220 A CN 201810796220A CN 109010343 A CN109010343 A CN 109010343A
- Authority
- CN
- China
- Prior art keywords
- base
- alkyl
- methyl
- chloro
- amino
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 0 CC(c1cc(*)c(*)c(C2CN(*)C2)c1*)[n]1nc(C)c2c1ncnc2N Chemical compound CC(c1cc(*)c(*)c(C2CN(*)C2)c1*)[n]1nc(C)c2c1ncnc2N 0.000 description 8
- PMWGIVRHUIAIII-UHFFFAOYSA-N CC(C(O)=O)(F)F Chemical compound CC(C(O)=O)(F)F PMWGIVRHUIAIII-UHFFFAOYSA-N 0.000 description 1
- KVXTVARPRRDFIC-UHFFFAOYSA-N CC(C)N(C1)CC1c(c(C)c(cc1C(C)[n]2nc(C)c3c2ncnc3N)Cl)c1OC Chemical compound CC(C)N(C1)CC1c(c(C)c(cc1C(C)[n]2nc(C)c3c2ncnc3N)Cl)c1OC KVXTVARPRRDFIC-UHFFFAOYSA-N 0.000 description 1
- UTFBQQOQONRNOF-UHFFFAOYSA-N CC(c1cc(Cl)c(C)c(-c(nc2)ccc2C(N(C)C)=O)c1OCC[F]C(C(O)=O)(F)F)Nc1ncnc(N)c1C(C)=N Chemical compound CC(c1cc(Cl)c(C)c(-c(nc2)ccc2C(N(C)C)=O)c1OCC[F]C(C(O)=O)(F)F)Nc1ncnc(N)c1C(C)=N UTFBQQOQONRNOF-UHFFFAOYSA-N 0.000 description 1
- UKMNUUZQQCQJSP-UHFFFAOYSA-N CC(c1cc(Cl)c(C)c(C(C2)CC2O)c1OC[F]C(C(O)=C1CC1)(F)F)[n]1nc(C)c2c1ncnc2N Chemical compound CC(c1cc(Cl)c(C)c(C(C2)CC2O)c1OC[F]C(C(O)=C1CC1)(F)F)[n]1nc(C)c2c1ncnc2N UKMNUUZQQCQJSP-UHFFFAOYSA-N 0.000 description 1
- IMLHIRHIJBANDD-UHFFFAOYSA-N CCOc(c(C(C)=O)c1)c(C=C)c(F)c1Cl Chemical compound CCOc(c(C(C)=O)c1)c(C=C)c(F)c1Cl IMLHIRHIJBANDD-UHFFFAOYSA-N 0.000 description 1
- ZQPDJCIXJHUERQ-UHFFFAOYSA-N CCOc(c(C(C)[n]1nc(C)c2c1ncnc2N)c1)c(C(C2)CNC2=O)c(F)c1Cl Chemical compound CCOc(c(C(C)[n]1nc(C)c2c1ncnc2N)c1)c(C(C2)CNC2=O)c(F)c1Cl ZQPDJCIXJHUERQ-UHFFFAOYSA-N 0.000 description 1
- UKFAGMZZZSPUFZ-UHFFFAOYSA-N CCOc(c(C1(C)OCCO1)c1)c(C(C2)CNC2=O)c(F)c1Cl Chemical compound CCOc(c(C1(C)OCCO1)c1)c(C(C2)CNC2=O)c(F)c1Cl UKFAGMZZZSPUFZ-UHFFFAOYSA-N 0.000 description 1
- VXDSZRICEQLKCZ-UHFFFAOYSA-N CCOc(c(C1CN(C)C1)c1C#N)c(C(C)[n]2nc(C)c3c(N)ncnc23)cc1Cl Chemical compound CCOc(c(C1CN(C)C1)c1C#N)c(C(C)[n]2nc(C)c3c(N)ncnc23)cc1Cl VXDSZRICEQLKCZ-UHFFFAOYSA-N 0.000 description 1
- DTQVDTLACAAQTR-UHFFFAOYSA-N OC(C(F)(F)F)=O Chemical compound OC(C(F)(F)F)=O DTQVDTLACAAQTR-UHFFFAOYSA-N 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/5375—1,4-Oxazines, e.g. morpholine
- A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Epidemiology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Immunology (AREA)
- Pain & Pain Management (AREA)
- Rheumatology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201361771480P | 2013-03-01 | 2013-03-01 | |
| US61/771,480 | 2013-03-01 | ||
| CN201480021187.1A CN105120871B (zh) | 2013-03-01 | 2014-02-28 | 吡唑并嘧啶衍生物治疗PI3Kδ相关病症的用途 |
Related Parent Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201480021187.1A Division CN105120871B (zh) | 2013-03-01 | 2014-02-28 | 吡唑并嘧啶衍生物治疗PI3Kδ相关病症的用途 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN109010343A true CN109010343A (zh) | 2018-12-18 |
Family
ID=50288319
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201810796220.8A Pending CN109010343A (zh) | 2013-03-01 | 2014-02-28 | 吡唑并嘧啶衍生物治疗PI3Kδ相关病症的用途 |
| CN201480021187.1A Active CN105120871B (zh) | 2013-03-01 | 2014-02-28 | 吡唑并嘧啶衍生物治疗PI3Kδ相关病症的用途 |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201480021187.1A Active CN105120871B (zh) | 2013-03-01 | 2014-02-28 | 吡唑并嘧啶衍生物治疗PI3Kδ相关病症的用途 |
Country Status (32)
| Country | Link |
|---|---|
| US (6) | US9932341B2 (https=) |
| EP (3) | EP4233869A3 (https=) |
| JP (5) | JP6545106B2 (https=) |
| KR (5) | KR102586858B1 (https=) |
| CN (2) | CN109010343A (https=) |
| AR (1) | AR094964A1 (https=) |
| AU (5) | AU2014223257B2 (https=) |
| BR (1) | BR112015020941A2 (https=) |
| CA (1) | CA2901993C (https=) |
| CL (1) | CL2015002442A1 (https=) |
| CR (1) | CR20150472A (https=) |
| CY (1) | CY1122712T1 (https=) |
| DK (1) | DK2961410T3 (https=) |
| EA (2) | EA201591612A1 (https=) |
| ES (2) | ES2945212T3 (https=) |
| HR (1) | HRP20200263T1 (https=) |
| HU (1) | HUE047719T2 (https=) |
| IL (6) | IL301180A (https=) |
| LT (1) | LT2961410T (https=) |
| MX (2) | MX367713B (https=) |
| MY (1) | MY177875A (https=) |
| PE (1) | PE20151996A1 (https=) |
| PH (3) | PH12021552233A1 (https=) |
| PL (1) | PL2961410T3 (https=) |
| PT (1) | PT2961410T (https=) |
| RS (1) | RS59958B1 (https=) |
| SG (3) | SG10201707130UA (https=) |
| SI (1) | SI2961410T1 (https=) |
| SM (1) | SMT202000043T1 (https=) |
| TW (5) | TWI687220B (https=) |
| UA (1) | UA119641C2 (https=) |
| WO (1) | WO2014134426A1 (https=) |
Families Citing this family (35)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| KR101763656B1 (ko) | 2009-06-29 | 2017-08-01 | 인사이트 홀딩스 코포레이션 | Ｐｉ3ｋ 저해물질로서의 피리미디논 |
| PT3513793T (pt) | 2011-09-02 | 2021-05-10 | Incyte Holdings Corp | Heterociclilaminas como inibidores de pi3k |
| AR090548A1 (es) | 2012-04-02 | 2014-11-19 | Incyte Corp | Azaheterociclobencilaminas biciclicas como inhibidores de pi3k |
| ES2649156T3 (es) | 2013-01-14 | 2018-01-10 | Incyte Holdings Corporation | Compuestos bicíclicos de carboxamida aromática útiles como inhibidores de quinasas Pim |
| PE20191245A1 (es) | 2013-01-15 | 2019-09-18 | Incyte Holdings Corp | Compuestos de tiazolcarboxamidas y piridinacarboxamida utiles como inhibidores de quinasa pim |
| TWI687220B (zh) * | 2013-03-01 | 2020-03-11 | 美商英塞特控股公司 | 吡唑并嘧啶衍生物治療PI3Kδ相關病症之用途 |
| EA201690458A1 (ru) | 2013-08-23 | 2016-07-29 | Инсайт Корпорейшн | Фуро- и тиенопиридинкарбоксамиды, используемые в качестве ингибиторов pim-киназы |
| SI3129021T1 (sl) | 2014-04-08 | 2021-07-30 | Incyte Corporation | Zdravljenje malignosti B-celic s kombinacijo zaviralcev JAK in PI3K |
| WO2015191677A1 (en) | 2014-06-11 | 2015-12-17 | Incyte Corporation | Bicyclic heteroarylaminoalkyl phenyl derivatives as pi3k inhibitors |
| US9580418B2 (en) | 2014-07-14 | 2017-02-28 | Incyte Corporation | Bicyclic aromatic carboxamide compounds useful as Pim kinase inhibitors |
| US9822124B2 (en) | 2014-07-14 | 2017-11-21 | Incyte Corporation | Bicyclic heteroaromatic carboxamide compounds useful as Pim kinase inhibitors |
| WO2016130501A1 (en) | 2015-02-09 | 2016-08-18 | Incyte Corporation | Aza-heteroaryl compounds as pi3k-gamma inhibitors |
| SG10201907576SA (en) * | 2015-02-27 | 2019-09-27 | Incyte Corp | Salts of pi3k inhibitor and processes for their preparation |
| US9988401B2 (en) | 2015-05-11 | 2018-06-05 | Incyte Corporation | Crystalline forms of a PI3K inhibitor |
| WO2016196244A1 (en) | 2015-05-29 | 2016-12-08 | Incyte Corporation | Pyridineamine compounds useful as pim kinase inhibitors |
| TWI734699B (zh) | 2015-09-09 | 2021-08-01 | 美商英塞特公司 | Ｐｉｍ激酶抑制劑之鹽 |
| US9920032B2 (en) | 2015-10-02 | 2018-03-20 | Incyte Corporation | Heterocyclic compounds useful as pim kinase inhibitors |
| PT3371190T (pt) | 2015-11-06 | 2022-07-08 | Incyte Corp | Compostos heterocíclicos como inibidores de pi3k-gamma |
| US20170190689A1 (en) | 2016-01-05 | 2017-07-06 | Incyte Corporation | Pyridine and pyridimine compounds as pi3k-gamma inhibitors |
| EP3795563B1 (en) | 2016-03-31 | 2024-07-17 | Oncternal Therapeutics, Inc. | Indoline analogs and uses thereof |
| US10138248B2 (en) | 2016-06-24 | 2018-11-27 | Incyte Corporation | Substituted imidazo[2,1-f][1,2,4]triazines, substituted imidazo[1,2-a]pyridines, substituted imidazo[1,2-b]pyridazines and substituted imidazo[1,2-a]pyrazines as PI3K-γ inhibitors |
| BR112020004500A2 (pt) * | 2017-09-08 | 2020-12-01 | Beigene, Ltd. | derivados de imidazo [1,5-a] pirazina como inibidores de pi3kdelta |
| KR102717072B1 (ko) | 2017-10-18 | 2024-10-15 | 인사이트 코포레이션 | Pi3k-감마 저해제로서의 3차 하이드록시기로 치환된 축합된 이미다졸 유도체 |
| WO2019113487A1 (en) | 2017-12-08 | 2019-06-13 | Incyte Corporation | Low dose combination therapy for treatment of myeloproliferative neoplasms |
| WO2019137927A1 (en) * | 2018-01-10 | 2019-07-18 | Idorsia Pharmaceuticals Ltd | 2,4,6,7-tetrahydro-pyrazolo[4,3-d]pyrimidin-5-one derivatives and related compounds as c5a receptor modulators for treating vasculitis and inflammatory diseases |
| BR112020018094A2 (pt) | 2018-03-08 | 2020-12-22 | Incyte Corporation | Compostos de aminopirazina diol como inibidores de pi3k-¿ |
| SG11202011680YA (en) | 2018-06-01 | 2020-12-30 | Incyte Corp | Dosing regimen for the treatment of pi3k related disorders |
| US11046658B2 (en) | 2018-07-02 | 2021-06-29 | Incyte Corporation | Aminopyrazine derivatives as PI3K-γ inhibitors |
| TWI727392B (zh) * | 2018-08-13 | 2021-05-11 | 美商基利科學股份有限公司 | 噻二唑irak4抑制劑 |
| CN110833552A (zh) * | 2018-08-15 | 2020-02-25 | 广西梧州制药（集团）股份有限公司 | 吡唑并嘧啶衍生物在治疗狼疮肾炎的用途 |
| CR20250050A (es) * | 2018-09-05 | 2025-03-19 | Incyte Corp | Formas cristalinas de un inhibidor de fosfoinositida 3–quinasa (pi3k) (divisional 2021-0165) |
| WO2022115120A1 (en) | 2020-11-30 | 2022-06-02 | Incyte Corporation | Combination therapy with an anti-cd19 antibody and parsaclisib |
| EP4251138A1 (en) | 2020-11-30 | 2023-10-04 | Incyte Corporation | Combination therapy with an anti-cd19 antibody and parsaclisib |
| CN112808550B (zh) * | 2020-12-28 | 2021-10-01 | 青岛理工大学 | 用于海洋工程的劣化免疫仿生防护界面及制备方法 |
| US20230190755A1 (en) | 2021-12-16 | 2023-06-22 | Incyte Corporation | Topical formulations of PI3K-delta inhibitors |
Citations (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5521184A (en) * | 1992-04-03 | 1996-05-28 | Ciba-Geigy Corporation | Pyrimidine derivatives and processes for the preparation thereof |
| WO2010036380A1 (en) * | 2008-09-26 | 2010-04-01 | Intellikine, Inc. | Heterocyclic kinase inhibitors |
| WO2013033569A1 (en) * | 2011-09-02 | 2013-03-07 | Incyte Corporation | Heterocyclylamines as pi3k inhibitors |
Family Cites Families (37)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| PT1107964E (pt) | 1998-08-11 | 2010-06-11 | Novartis Ag | Derivados de isoquinolina com actividade inibidora da angiogénese |
| US6133031A (en) | 1999-08-19 | 2000-10-17 | Isis Pharmaceuticals Inc. | Antisense inhibition of focal adhesion kinase expression |
| GB9905075D0 (en) | 1999-03-06 | 1999-04-28 | Zeneca Ltd | Chemical compounds |
| GB0004890D0 (en) | 2000-03-01 | 2000-04-19 | Astrazeneca Uk Ltd | Chemical compounds |
| KR100786927B1 (ko) | 2000-06-28 | 2007-12-17 | 스미스클라인비이참피이엘시이 | 습식 분쇄방법 |
| BR0212760A (pt) | 2001-09-19 | 2004-12-07 | Aventis Pharma Sa | Compostos quìmicos |
| DE60213842T2 (de) | 2001-10-30 | 2007-09-06 | Novartis Ag | Staurosporin-derivate als hemmer der flt3-rezeptor-tyrosinkinase-wirkung |
| PE20040522A1 (es) | 2002-05-29 | 2004-09-28 | Novartis Ag | Derivados de diarilurea dependientes de la cinasa de proteina |
| GB0215676D0 (en) | 2002-07-05 | 2002-08-14 | Novartis Ag | Organic compounds |
| TWI335913B (en) | 2002-11-15 | 2011-01-11 | Vertex Pharma | Diaminotriazoles useful as inhibitors of protein kinases |
| UA80767C2 (en) | 2002-12-20 | 2007-10-25 | Pfizer Prod Inc | Pyrimidine derivatives for the treatment of abnormal cell growth |
| GB0305929D0 (en) | 2003-03-14 | 2003-04-23 | Novartis Ag | Organic compounds |
| AR045944A1 (es) | 2003-09-24 | 2005-11-16 | Novartis Ag | Derivados de isoquinolina 1.4-disustituidas |
| RU2401265C2 (ru) | 2004-06-10 | 2010-10-10 | Айрм Ллк | Соединения и композиции в качестве ингибиторов протеинкиназы |
| AU2005309019A1 (en) | 2004-11-24 | 2006-06-01 | Novartis Ag | Combinations of JAK inhibitors and at least one of Bcr-Abl, Flt-3, FAK or RAF kinase inhibitors |
| UA95940C2 (uk) | 2006-01-17 | 2011-09-26 | Вертекс Фармасьютикалс Інкорпорейтед | Азаіндоли як інгібітори кіназ януса |
| TW200916447A (en) | 2007-08-29 | 2009-04-16 | Methylgene Inc | Sirtuin inhibitors |
| US20110105500A1 (en) | 2008-06-27 | 2011-05-05 | S*Bio Pte Ltd. | Pyrazine substituted purines |
| AR073651A1 (es) * | 2008-09-24 | 2010-11-24 | Novartis Ag | Formulaciones galenicas de compuestos organicos |
| AU2010234360A1 (en) | 2009-04-09 | 2011-09-29 | Oncothyreon, Incorporated | Methods and compositions of PI-3 kinase inhibitors for treating fibrosis |
| KR101763656B1 (ko) | 2009-06-29 | 2017-08-01 | 인사이트 홀딩스 코포레이션 | Ｐｉ3ｋ 저해물질로서의 피리미디논 |
| US8293753B2 (en) | 2009-07-02 | 2012-10-23 | Novartis Ag | Substituted 2-carboxamide cycloamino ureas |
| HRP20130951T1 (hr) | 2009-08-28 | 2013-11-22 | Takeda Pharmaceutical Company Limited | Spojevi heksahidrooksazinopteridina za uporabu kao inhibitori mtor |
| TW201130842A (en) | 2009-12-18 | 2011-09-16 | Incyte Corp | Substituted fused aryl and heteroaryl derivatives as PI3K inhibitors |
| US8759359B2 (en) | 2009-12-18 | 2014-06-24 | Incyte Corporation | Substituted heteroaryl fused derivatives as PI3K inhibitors |
| EP2558463A1 (en) | 2010-04-14 | 2013-02-20 | Incyte Corporation | Fused derivatives as i3 inhibitors |
| WO2011163195A1 (en) | 2010-06-21 | 2011-12-29 | Incyte Corporation | Fused pyrrole derivatives as pi3k inhibitors |
| EP3660016A1 (en) | 2010-12-20 | 2020-06-03 | Incyte Holdings Corporation | N-(1-(substituted-phenyl)ethyl)-9h-purin-6-amines as pi3k inhibitors |
| AU2012212323A1 (en) | 2011-02-01 | 2013-09-12 | The Board Of Trustees Of The University Of Illinois | HDAC inhibitors and therapeutic methods using the same |
| US9108984B2 (en) | 2011-03-14 | 2015-08-18 | Incyte Corporation | Substituted diamino-pyrimidine and diamino-pyridine derivatives as PI3K inhibitors |
| WO2012135009A1 (en) | 2011-03-25 | 2012-10-04 | Incyte Corporation | Pyrimidine-4,6-diamine derivatives as pi3k inhibitors |
| AR090548A1 (es) | 2012-04-02 | 2014-11-19 | Incyte Corp | Azaheterociclobencilaminas biciclicas como inhibidores de pi3k |
| TWI687220B (zh) | 2013-03-01 | 2020-03-11 | 美商英塞特控股公司 | 吡唑并嘧啶衍生物治療PI3Kδ相關病症之用途 |
| WO2015191677A1 (en) * | 2014-06-11 | 2015-12-17 | Incyte Corporation | Bicyclic heteroarylaminoalkyl phenyl derivatives as pi3k inhibitors |
| SG10201907576SA (en) | 2015-02-27 | 2019-09-27 | Incyte Corp | Salts of pi3k inhibitor and processes for their preparation |
| SG11202011680YA (en) | 2018-06-01 | 2020-12-30 | Incyte Corp | Dosing regimen for the treatment of pi3k related disorders |
| WO2020102150A1 (en) * | 2018-11-13 | 2020-05-22 | Incyte Corporation | Heterocyclic derivatives as pi3k inhibitors |
-
2014
- 2014-02-27 TW TW108100664A patent/TWI687220B/zh active
- 2014-02-27 TW TW112117019A patent/TWI841376B/zh active
- 2014-02-27 TW TW103106906A patent/TWI657090B/zh active
- 2014-02-27 TW TW110124946A patent/TW202214254A/zh unknown
- 2014-02-27 TW TW109104878A patent/TWI736135B/zh active
- 2014-02-28 ES ES19208523T patent/ES2945212T3/es active Active
- 2014-02-28 CA CA2901993A patent/CA2901993C/en active Active
- 2014-02-28 ES ES14710739T patent/ES2774436T3/es active Active
- 2014-02-28 KR KR1020227035039A patent/KR102586858B1/ko active Active
- 2014-02-28 PL PL14710739T patent/PL2961410T3/pl unknown
- 2014-02-28 SG SG10201707130UA patent/SG10201707130UA/en unknown
- 2014-02-28 AR ARP140100679A patent/AR094964A1/es unknown
- 2014-02-28 BR BR112015020941A patent/BR112015020941A2/pt not_active Application Discontinuation
- 2014-02-28 KR KR1020247033698A patent/KR20240152422A/ko active Pending
- 2014-02-28 WO PCT/US2014/019372 patent/WO2014134426A1/en not_active Ceased
- 2014-02-28 EP EP23161858.8A patent/EP4233869A3/en active Pending
- 2014-02-28 PE PE2015001833A patent/PE20151996A1/es not_active Application Discontinuation
- 2014-02-28 SI SI201431449T patent/SI2961410T1/sl unknown
- 2014-02-28 EP EP14710739.5A patent/EP2961410B1/en active Active
- 2014-02-28 CN CN201810796220.8A patent/CN109010343A/zh active Pending
- 2014-02-28 KR KR1020217027697A patent/KR102454308B1/ko active Active
- 2014-02-28 EP EP19208523.1A patent/EP3632442B1/en active Active
- 2014-02-28 MY MYPI2015002108A patent/MY177875A/en unknown
- 2014-02-28 SG SG10201912275YA patent/SG10201912275YA/en unknown
- 2014-02-28 IL IL301180A patent/IL301180A/en unknown
- 2014-02-28 EA EA201591612A patent/EA201591612A1/ru unknown
- 2014-02-28 AU AU2014223257A patent/AU2014223257B2/en active Active
- 2014-02-28 HU HUE14710739A patent/HUE047719T2/hu unknown
- 2014-02-28 SG SG11201506654UA patent/SG11201506654UA/en unknown
- 2014-02-28 IL IL311666A patent/IL311666A/en unknown
- 2014-02-28 HR HRP20200263TT patent/HRP20200263T1/hr unknown
- 2014-02-28 LT LTEP14710739.5T patent/LT2961410T/lt unknown
- 2014-02-28 MX MX2015011273A patent/MX367713B/es active IP Right Grant
- 2014-02-28 CN CN201480021187.1A patent/CN105120871B/zh active Active
- 2014-02-28 SM SM20200043T patent/SMT202000043T1/it unknown
- 2014-02-28 JP JP2015560346A patent/JP6545106B2/ja active Active
- 2014-02-28 UA UAA201509435A patent/UA119641C2/uk unknown
- 2014-02-28 PH PH1/2021/552233A patent/PH12021552233A1/en unknown
- 2014-02-28 DK DK14710739.5T patent/DK2961410T3/da active
- 2014-02-28 EA EA202192151A patent/EA202192151A1/ru unknown
- 2014-02-28 RS RS20200176A patent/RS59958B1/sr unknown
- 2014-02-28 KR KR1020157027010A patent/KR102298150B1/ko active Active
- 2014-02-28 US US14/193,481 patent/US9932341B2/en active Active
- 2014-02-28 KR KR1020237033761A patent/KR102717616B1/ko active Active
- 2014-02-28 PT PT147107395T patent/PT2961410T/pt unknown
-
2015
- 2015-08-24 IL IL240784A patent/IL240784B/en not_active IP Right Cessation
- 2015-08-28 MX MX2019010422A patent/MX2019010422A/es unknown
- 2015-08-31 CL CL2015002442A patent/CL2015002442A1/es unknown
- 2015-09-01 PH PH12015501920A patent/PH12015501920A1/en unknown
- 2015-09-10 CR CR20150472A patent/CR20150472A/es unknown
-
2018
- 2018-03-02 US US15/910,708 patent/US20190040067A1/en not_active Abandoned
- 2018-11-14 AU AU2018264053A patent/AU2018264053B2/en active Active
-
2019
- 2019-04-25 JP JP2019084393A patent/JP6776399B2/ja active Active
- 2019-06-11 PH PH12019501321A patent/PH12019501321A1/en unknown
- 2019-07-04 IL IL267853A patent/IL267853B/en active IP Right Grant
-
2020
- 2020-02-26 CY CY20201100177T patent/CY1122712T1/el unknown
- 2020-05-19 IL IL274771A patent/IL274771A/en unknown
- 2020-07-31 AU AU2020210278A patent/AU2020210278B2/en active Active
- 2020-10-07 JP JP2020169551A patent/JP7189185B2/ja active Active
-
2021
- 2021-06-13 IL IL283943A patent/IL283943B2/en unknown
- 2021-06-30 US US17/364,585 patent/US20220119393A1/en not_active Abandoned
- 2021-06-30 US US17/364,551 patent/US12152033B2/en active Active
- 2021-06-30 US US17/364,695 patent/US20210332059A1/en not_active Abandoned
-
2022
- 2022-08-16 AU AU2022218495A patent/AU2022218495B2/en active Active
- 2022-12-01 JP JP2022192954A patent/JP7556010B2/ja active Active
-
2024
- 2024-09-11 JP JP2024157116A patent/JP2025003975A/ja active Pending
- 2024-10-24 US US18/926,010 patent/US20250289823A1/en active Pending
- 2024-12-23 AU AU2024287194A patent/AU2024287194A1/en active Pending
Patent Citations (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5521184A (en) * | 1992-04-03 | 1996-05-28 | Ciba-Geigy Corporation | Pyrimidine derivatives and processes for the preparation thereof |
| WO2010036380A1 (en) * | 2008-09-26 | 2010-04-01 | Intellikine, Inc. | Heterocyclic kinase inhibitors |
| WO2013033569A1 (en) * | 2011-09-02 | 2013-03-07 | Incyte Corporation | Heterocyclylamines as pi3k inhibitors |
Non-Patent Citations (1)
| Title |
|---|
| 王鸿利等: "《临床血液实验学》", 31 October 2013, 上海科学技术出版社 * |
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN109010343A (zh) | 吡唑并嘧啶衍生物治疗PI3Kδ相关病症的用途 | |
| CN106986867B (zh) | 作为pi3k抑制剂的杂环基胺 | |
| US11130767B2 (en) | Bicyclic heteroarylaminoalkyl phenyl derivatives as PI3K inhibitors | |
| CN104024253B (zh) | 作为pi3k抑制剂的杂环基胺 |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PB01 | Publication | ||
| PB01 | Publication | ||
| SE01 | Entry into force of request for substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| RJ01 | Rejection of invention patent application after publication | ||
| RJ01 | Rejection of invention patent application after publication |
Application publication date: 20181218 |